Sentence examples for be a negative predictive from inspiring English sources

21 In their study, KRAS mutation was found to be a negative predictive and prognostic factor.

KRAS was shown to be a negative predictive biomarker for AZD5363 response [ 9].

On the contrary, they have been evidenced to be a negative predictive factor in patients treated with platinum chemotherapy, in both adjuvant and metastatic setting, probably because of an association between ERCC1 expression and platinum resistance as shown in NSCLC, ovarian and gastroenteric tumours (Li et al, 2000; Joshi et al, 2005; Gazdar, 2007).

HOXB13 : is17BR is an independent prognostic factor for patients with oestrogen receptor (ER) positive and node negative disease that has also been shown to be a negative predictive factor of tamoxifen benefit (Ma et al, 2004, 2006; Goetz et al, 2006; Jerevall et al, 2008).

In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.

The recently reported results from a randomized adjuvant study however have shown that a high SPARC expression is a negative predictive biomarker of adjuvant gemcitabine benefit [ 39].

Studies, using CT-based response evaluation, have shown that KRAS mutation is a negative predictive marker of morphologic response to the monoclonal antibody cetuximab 17, 18.

By multivariate analysis, considering chemotherapy response, ERCC1 was a negative predictive marker for response rate (adjusted OR 5.038, 95% CI 2.44-10.37, P = 0.001).

KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC).

Since the initial observation that KRAS mutation (exon 2, 3 en 4) is a negative predictive factor for anti-EGFR therapy [ 21], much effort has been made to further optimize patient selection for this therapy.

KRAS mutation is a negative predictive marker for response to EGFR-targeted therapy and clinical benefit seems to be restricted to patients with KRAS wild-type tumors [ 2- 5, 8, 9].